126 related articles for article (PubMed ID: 9026840)
1. [A comparison of bezafibrate and lovastatin treatment at the usual doses in post-heart transplant hyperlipemia].
Zambrana García JL; López Miranda J; Anguita Sánchez M; Blanco Cerrada J; Vallés Belsúe F; Casares Mediavilla J; Muñoz Carvajal I; Jiménez Perepérez JA; Pérez Jiménez F
Rev Esp Cardiol; 1996 Dec; 49(12):892-8. PubMed ID: 9026840
[TBL] [Abstract][Full Text] [Related]
2. Lovastatin versus bezafibrate for hyperlipemia treatment after heart transplantation.
Hidalgo L; Zambrana JL; Blanco-Molina A; López-Granados A; Concha M; Casares J; Jiménez-Pérez J; López-Miranda J; Pérez-Jiménez F
J Heart Lung Transplant; 1995; 14(3):461-7. PubMed ID: 7654731
[TBL] [Abstract][Full Text] [Related]
3. Bezafibrate and lovastatin decrease the oxidizability of low-density lipoproteins in heart transplant recipients with hyperlidemia.
Zambrana JL; López-Miranda J; Blanco A; Arizón JM; Jansen S; Paniagua JA; Jimenéz-Perepérez JA; Concha M; Pérez-Jiménez F
J Heart Lung Transplant; 1998 Dec; 17(12):1213-9. PubMed ID: 9883763
[TBL] [Abstract][Full Text] [Related]
4. Cholesterol-lowering therapy after heart transplantation: a 12-month randomized trial.
Pflugfelder PW; Huff M; Oskalns R; Rudas L; Kostuk WJ
J Heart Lung Transplant; 1995; 14(4):613-22. PubMed ID: 7578166
[TBL] [Abstract][Full Text] [Related]
5. Treatment of severe, resistant familial combined hyperlipidemia with a bezafibrate-lovastatin combination.
Yeshurun D; Abukarshin R; Elias N; Lanir A; Naschitz JE
Clin Ther; 1993; 15(2):355-63. PubMed ID: 8519043
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of low dose simvastatin in cardiac transplant recipients treated with cyclosporine.
Vanhaecke J; Van Cleemput J; Van Lierde J; Daenen W; De Geest H
Transplantation; 1994 Jul; 58(1):42-5. PubMed ID: 8036706
[TBL] [Abstract][Full Text] [Related]
7. Efficacy, safety and tolerability of lovastatin and bezafibrate retard in patients with hypercholesterolemia.
Schumacher M; Eber B; Silberbauer K; Breier C; Stühlinger W; Schmidt P; Gaul G; Klein W
Acta Med Austriaca; 1992; 19(5):140-4. PubMed ID: 1298143
[TBL] [Abstract][Full Text] [Related]
8. Combination therapy with low-dose lovastatin and niacin is as effective as higher-dose lovastatin.
Gardner SF; Schneider EF; Granberry MC; Carter IR
Pharmacotherapy; 1996; 16(3):419-23. PubMed ID: 8726600
[TBL] [Abstract][Full Text] [Related]
9. Effects of policosanol and lovastatin on lipid profile and lipid peroxidation in patients with dyslipidemia associated with type 2 diabetes mellitus.
Castaño G; Menéndez R; Más R; Amor A; Fernández JL; González RL; Lezcay M; Alvarez E
Int J Clin Pharmacol Res; 2002; 22(3-4):89-99. PubMed ID: 12837046
[TBL] [Abstract][Full Text] [Related]
10. Comparison of bezafibrate versus lovastatin for lowering plasma insulin, fibrinogen, and plasminogen activator inhibitor-1 concentrations in hyperlipemic heart transplant patients.
Zambrana JL; Velasco F; Castro P; Concha M; Vallés F; Montilla P; Jimenéz-Perepérez JA; López-Miranda J; Pérez-Jiménez F
Am J Cardiol; 1997 Oct; 80(7):836-40. PubMed ID: 9381994
[TBL] [Abstract][Full Text] [Related]
11. Low-dose lovastatin safely lowers cholesterol after cardiac transplantation.
Kobashigawa JA; Murphy FL; Stevenson LW; Moriguchi JD; Kawata N; Kamjoo P; Brownfield E; Wilmarth J; Leonard L; Chuck C
Circulation; 1990 Nov; 82(5 Suppl):IV281-3. PubMed ID: 2225417
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of rosuvastatin therapy for the prevention of hyperlipidemia in adult cardiac transplant recipients.
Samman A; Imai C; Straatman L; Frolich J; Humphries K; Ignaszewski A
J Heart Lung Transplant; 2005 Aug; 24(8):1008-13. PubMed ID: 16102434
[TBL] [Abstract][Full Text] [Related]
13. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial.
Derosa G; Cicero AE; Bertone G; Piccinni MN; Ciccarelli L; Roggeri DE
Clin Ther; 2004 Oct; 26(10):1599-607. PubMed ID: 15598476
[TBL] [Abstract][Full Text] [Related]
14. Lipid-lowering effects of lovastatin in CAPD patients.
Jacobs RH; Lal SM; Nolph KD
Adv Perit Dial; 1993; 9():288-90. PubMed ID: 8105945
[TBL] [Abstract][Full Text] [Related]
15. Niacin-based therapy for dyslipidemia: past evidence and future advances.
Ito MK
Am J Manag Care; 2002 Sep; 8(12 Suppl):S315-22. PubMed ID: 12240703
[TBL] [Abstract][Full Text] [Related]
16. Genetic variation in the hepatic lipase gene is associated with combined hyperlipidemia, plasma lipid concentrations, and lipid-lowering drug response.
Cenarro A; Artieda M; Gonzalvo C; Meriño-Ibarra E; Arístegui R; Gañán A; Díaz C; Sol JM; Pocoví M; Civeira F;
Am Heart J; 2005 Dec; 150(6):1154-62. PubMed ID: 16338252
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of once-daily extended-release lovastatin as compared to immediate-release lovastatin in patients with hypercholesterolemia.
Lukacsko P; Walters EJ; Cullen EI; Niecestro R; Friedhoff LT
Curr Med Res Opin; 2004 Jan; 20(1):13-8. PubMed ID: 14741066
[TBL] [Abstract][Full Text] [Related]
18. Beneficial effects of atorvastatin in the treatment of hyperlipidemia after renal transplantation.
Demetriou D; Shabpar A; Böhmig G; Schmaldienst S; Hörl WH; Watschinger B
Wien Klin Wochenschr; 2000 Apr; 112(8):358-61. PubMed ID: 10849941
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the efficacy and safety of atorvastatin initiated at different starting doses in patients with dyslipidemia.
Jones PH; McKenney JM; Karalis DG; Downey J
Am Heart J; 2005 Jan; 149(1):e1. PubMed ID: 15660024
[TBL] [Abstract][Full Text] [Related]
20. Fluvastatin in combination with other lipid-lowering agents.
Jokubaitis LA
Br J Clin Pract Suppl; 1994 Dec; (77):28-32. PubMed ID: 19496270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
